S
Sue Moss
Researcher at Queen Mary University of London
Publications - 220
Citations - 23534
Sue Moss is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Mass screening & Breast cancer. The author has an hindex of 62, co-authored 218 publications receiving 21842 citations. Previous affiliations of Sue Moss include The Royal Marsden NHS Foundation Trust & St James's University Hospital.
Papers
More filters
Journal ArticleDOI
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,A. Berenguer,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Bert G. Blijenberg,Sue Moss,Harry J. de Koning,Anssi Auvinen +21 more
TL;DR: PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis.
Journal ArticleDOI
Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
Jack D. Hardcastle,Jocelyn Chamberlain,Michael Robinson,Sue Moss,Satya S Amar,Tom Balfour,Peter D. James,Christine M Mangham +7 more
TL;DR: Evidence from this study and other trials suggest that consideration should be given to a national programme of FOB screening to reduce CRC mortality in the general population.
Journal ArticleDOI
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Teuvo L.J. Tammela,Marco Zappa,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Liisa Määttänen,Hans Lilja,Louis Denis,Franz Recker,Alvaro Paez,Chris H. Bangma,Sigrid Carlsson,Sigrid Carlsson,Donella Puliti,Arnauld Villers,Xavier Rebillard,Matti Hakama,Ulf-Håkan Stenman,Paula Kujala,Kimmo Taari,Gunnar Aus,Andreas R. Huber,Theo van der Kwast,Ron H.N. van Schaik,Harry J. de Koning,Sue Moss,Anssi Auvinen +29 more
TL;DR: In this update the ERSPC confirms a substantial reduction in prostate cancer mortality attributable to testing of PSA, with a substantially increased absolute effect at 13 years compared with findings after 9 and 11 years.
Journal ArticleDOI
Prostate-Cancer Mortality at 11 Years of Follow-up
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,Alvaro Paez,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Sigrid Carlsson,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Paula Kujala,Bert G. Blijenberg,Ulf-Håkan Stenman,Andreas R. Huber,Kimmo Taari,Matti Hakama,Sue Moss,Harry J. de Koning,Anssi Auvinen +27 more
TL;DR: Analyses after 2 additional years of follow-up consolidated the previous finding that PSA-based screening significantly reduced mortality from prostate cancer but did not affect all-cause mortality.
Journal ArticleDOI
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
Martin O. Leach,Caroline Boggis,Adrian K. Dixon,Douglas F. Easton,Rosalind A. Eeles,D G R Evans,Fiona J. Gilbert,I Griebsch,Rebecca Hoff,Preminda Kessar,Sunil R. Lakhani,Sue Moss,Ashutosh Nerurkar,Anwar R. Padhani,Linda Pointon,Deborah J. Thompson,Ruth Warren +16 more
TL;DR: In this paper, the authors compared contrast enhanced magnetic resonance imaging (CE MRI) with mammography for screening of women genetically predisposed to breast cancer and found that CE MRI is more sensitive than mammography.